Interleukin Gene Expression Prediction for Radiotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the response of prostate cancer patients to radiotherapy are inadequate, leading to uncertainty in treatment effectiveness and increased side effects, particularly for patients at higher risk of recurrence, where existing biomarkers provide limited improvements in patient stratification and therapy selection.
Innovation Solution
A method utilizing gene expression profiles of three or more interleukin genes (IL17RE, IL1B, IL3, IL7R, IL9R, and EBI3) to predict radiotherapy response, which involves determining these profiles in a biological sample and using a regression function to provide a prediction or therapy recommendation, potentially adjusting treatment approaches based on the predicted effectiveness of radiotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiotherapy is administered to prostate cancer patients, then treatment effectiveness is improved, but side effects and treatment costs increase
Solution Approach 1:
The patent applies preliminary action by determining gene expression profiles of interleukin genes (IL17RE, IL1B, IL3, IL7R, IL9R, EBI3) in biological samples before radiotherapy treatment to predict treatment response. This allows clinicians to identify patients likely to benefit from radiotherapy beforehand, avoiding unnecessary treatment and its associated side effects for patients who would not respond well.
Solution Approach 2:
The patent utilizes parameter changes by measuring gene expression levels of specific interleukin genes as biomarkers. The expression profiles of these genes serve as predictive parameters that indicate treatment response, enabling personalized treatment decisions based on molecular characteristics rather than uniform treatment protocols.
2Ease of operation
If existing biomarkers are used for patient stratification, then treatment guidance is provided, but prediction precision remains limited
Solution Approach 1:
The patent merges multiple gene expression measurements into a comprehensive predictive model. By combining the expression profiles of six interleukin genes (IL17RE, IL1B, IL3, IL7R, IL9R, EBI3), the patent creates a more precise predictive tool than single biomarker approaches, improving patient stratification accuracy for radiotherapy response.
Solution Approach 2:
The patent applies universality by using a multi-gene expression profile panel that can serve multiple purposes: predicting radiotherapy response, guiding treatment decisions, and potentially applying to different prostate cancer patient populations. This multi-functional biomarker panel enhances both ease of operation and prediction precision.
Data Source
AI summary
The invention relates to a method of predicting a response of a prostate cancer subject to radiotherapy, comprising determining or receiving the result of a determination of a gene expression profile for each of three or more interleukin genes selected from the group consisting of: IL17RE, IL1B, IL3, IL7R, IL9R, and EBI3, said gene expression profiles being determined in a biological sample obtained from the subject, and determining, preferably by a processor, the prediction of the radiotherapy response based on the gene expression profiles for the three or more interleukin genes.